When Robert Atchison and his colleagues at the University of Pittsburgh first stumbled across adeno-associated viruses (AAV) in 1965, they initially supposed they were merely defective byproducts ...

For central nervous system (CNS) applications, attempts are being made to deliver AAV gene therapy directly to the brain parenchyma or the cerebrospinal fluid (CSF) space by intra-cisterna magna ...

Gene therapy represents one of the fastest growing biotherapeutics worldwide, with AAV at the forefront. This rapid growth is constantly challenging CMC approaches, from manufacturing through release ...

That deal is worth $35 million per year in average annual salary, but he reportedly could have gotten an even bigger deal in AAV from the Baltimore Orioles. Roch Kubatko of MASN reported that the ...

Coave's proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid, ...